Philip Zakas

Philip Zakas is a Senior Scientist at Tessera Therapeutics, focusing on the biological characterization of lipid nanoparticle delivery to hepatic and extra-hepatic tissues, and identifying immunologic and metabolic response pathways that influence delivery. Previously, Zakas held various scientific roles, including Scientist II at Sanofi, where leadership was provided to a non-viral gene therapy platform targeting hemophilia A, and Scientist I roles at Bioverativ and Sanofi. Zakas completed a Postdoctoral Research Fellowship at Queen's University, working on ancestral sequence reconstruction of von Willebrand Factor, and earned a PhD in Molecular and Systems Pharmacology from Emory University. Zakas also has experience as a Project Officer at Irving Burton Associates, overseeing biomedical projects for the Department of Defense. Educational qualifications include a BS in Biology from Elon University.